139. Congenital cerebral hypomyelination
[
5 clinical trials,
4 drugs（DrugBank:
1 drug),
0 target gene / 0 target pathway ]
Searched query = "Congenital cerebral hypomyelination", "Congenital cerebral white matter aplasia", "Pelizaeus Merzbacher disease", "Pelizaeus Merzbacher like disease ... show all
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02396459 | June 2019 | 8 April 2019 | Triac Trial II in MCT8 Patients | Effects of the Thyroid Hormone Analog Triac on the Neurocognitive Phenotype in Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial II | Allan-Herndon-Dudley Syndrome | Drug: Triac | Erasmus Medical Center | Not recruiting | N/A | 18 Years | Male | 30 | Phase 2 | Netherlands | |
| 2 | JPRN-jRCTs031180348 | 01/04/2018 | 2 April 2019 | Effectiveness of Curcumin for PMD | Effectiveness of Curcumin (an active integrant in turmeric) for Pelizaeus-Merzbacher disease: an exploratory study - Effectiveness of Curcumin for PMD | Pelizaeus-Merzbacher disease Neurology/Pediatrics;D020371;Neurology/Pediatrics | Low dose curcumin (1mg/kg/day, oral, once a day) for 2 months followed by high dose curcumin (4mg/kg/day, oral, once a day) for 10 months. | Ken Inoue | Recruiting | 5 | 20 | Male | 10 | N/A | None | |
| 3 | NCT02060474 | October 2014 | 29 April 2019 | Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients | Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial. | Allan-Herndon-Dudley Syndrome | Drug: Triac | Erasmus Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development | Not recruiting | N/A | 99 Years | Male | 46 | Phase 2 | Netherlands |
| 4 | NCT01391637 | June 2011 | 23 May 2016 | Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD) | Long-Term Follow-Up Safety and Preliminary Efficacy Study of Human Central Nervous System Stem Cell (HuCNS-SC®) Transplantation in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD) | Pelizaeus-Merzbacher Disease;PMD | Biological: HuCNS-SC transplant in the lead-in phase | StemCells, Inc. | Not recruiting | N/A | N/A | Male | 4 | Phase 1 | United States | |
| 5 | NCT01005004 | November 2009 | 19 February 2015 | Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects | Phase I Study of the Safety and Preliminary Efficacy of Intracerebral Transplantation of HuCNS-SC® Cells for Connatal Pelizaeus-Merzbacher Disease (PMD) | Pelizaeus-Merzbacher Disease | Biological: HuCNS-SC cells | StemCells, Inc. | Not recruiting | 6 Months | 5 Years | Male | 4 | Phase 1 | United States |